Previous 10 | Next 10 |
While inflation was at first believed to be transitory, it is now beginning to look persistent. Biotech stocks are close to 6.5% of the Russell 2000 Value Index benchmark, and only a few have earnings and positive cash flows. We also think the outlook is rosy for small-cap value i...
With each new outbreak and variant, comes new fears, government lockdowns and hopes for recovery through science and medicine in the form of effective vaccines. Until recently, investor mindsets had shifted to a “living with COVID-19” mentality, supported by abundant sti...
The latest IHS Markit US Sector PMI revealed that six of the seven broad sectors tracked by the surveys reported higher output in November. Despite some of the supply chain problems having eased in November, the extent to which production growth had been constrained is consistent with...
We are particularly enthused about a broad area that falls within the life science tools and services category, where we find many companies that are enabling innovative breakthroughs. Other growth themes in healthcare have either arisen or accelerated due to the COVID-19 pandemic. Th...
In making the case for less stringent regulations, pharmaceutical companies highlight the distinctions between list prices and net prices. The industry projects potential negative implications for patient access and R&D investments, and support in Congress has historically be limi...
The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....
Taking a look at how the expected Q3 ’21 sector revenue growth rates have changed since mid-August ’21 or the unofficial end of Q2 ’21 earnings season. Per Bespoke’s research, the S&P 500 has now reached “extremely oversold” levels, worse ...
Price pressures are most concentrated in those sectors reporting the greatest constraints. Output consequently fell in China as well as a number of other smaller Asia-Pacific economies, and growth slowed in the US and Europe. The constraints on production caused by a lack of input...
As the world convalesced from the pandemic, stocks advanced in the second quarter and earnings rebounded across sectors. With business gains broadening amid complex market risks, we think investors should lean on quality to find stocks that will perform well in a normalizing world eco...
As we mark the halfway point of the year, the economy is in full recovery mode and asset prices are soaring. As we enter the second half of the year though, it is hard to ignore some contradictions. Economic growth in H1 is going to print a big number, and yet, the 10-year Treasury no...
News, Short Squeeze, Breakout and More Instantly...
BLACKROCK ETF TRUS Company Name:
BMED Stock Symbol:
NYSE Market:
2024-07-17 12:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-07 19:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-06 20:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...